Phaseline

Targets › IL33

IL33 (Interleukin-33): drug programs, companies and trials

1 program from 1 company in 3 trials: 3 Phase 3; Respiratory; next expected readout Feb 2027.

Cytokine that binds to and signals through the IL1RL1/ST2 receptor which in turn activates NF-kappa-B and MAPK signaling pathways in target cells. Involved in the maturation of Th2 cells inducing the secretion of T-helper type 2-associated cytokines. (UniProt, O95760)

Open in Phaseline: the race on IL33, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
SanofiItepekimab (SAR440340)
Interleukin-33 inhibitor
IL33Phase 3Chronic Rhinosinusitis With Nasal PolypsFeb 2027

Conditions

Chronic Rhinosinusitis With Nasal Polyps (3)

Modalities

antibody (1)

Companies

Sanofi (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.